home / stock / icpt / icpt quote
Last: | $19 |
---|---|
Change Percent: | 0.0% |
Open: | $19 |
Close: | $19 |
High: | $19.01 |
Low: | $18.98 |
Volume: | 3,963,455 |
Last Trade Date Time: | 11/07/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$19 | $19 | $19 | $19.01 | $18.98 | 3,963,455 | 11-07-2023 |
$18.96 | $18.97 | $18.96 | $19.02 | $18.96 | 3,612,103 | 11-06-2023 |
$18.98 | $18.97 | $18.98 | $18.985 | $18.95 | 1,027,785 | 11-03-2023 |
$18.98 | $18.96 | $18.98 | $18.98 | $18.93 | 2,101,181 | 11-02-2023 |
$18.96 | $18.93 | $18.96 | $18.96 | $18.93 | 2,278,951 | 11-01-2023 |
$18.93 | $18.92 | $18.93 | $18.95 | $18.92 | 1,167,064 | 10-31-2023 |
$18.92 | $18.91 | $18.92 | $18.96 | $18.91 | 703,909 | 10-30-2023 |
$18.91 | $18.91 | $18.91 | $18.94 | $18.9 | 873,776 | 10-27-2023 |
$18.94 | $18.92 | $18.94 | $18.95 | $18.89 | 1,910,541 | 10-26-2023 |
$18.82 | $18.76 | $18.82 | $18.84 | $18.76 | 655,332 | 10-25-2023 |
$18.82 | $18.77 | $18.82 | $18.92 | $18.77 | 1,017,295 | 10-24-2023 |
$18.82 | $18.63 | $18.82 | $18.84 | $18.63 | 724,927 | 10-23-2023 |
$18.67 | $18.63 | $18.67 | $18.72 | $18.63 | 871,393 | 10-20-2023 |
$18.66 | $18.63 | $18.66 | $18.68 | $18.6 | 1,033,193 | 10-19-2023 |
$18.61 | $18.62 | $18.61 | $18.7306 | $18.6 | 1,416,791 | 10-18-2023 |
$18.62 | $18.61 | $18.62 | $18.66 | $18.56 | 1,579,195 | 10-17-2023 |
$18.66 | $18.55 | $18.66 | $18.68 | $18.54 | 2,713,985 | 10-16-2023 |
$18.2 | $18.94 | $18.2 | $18.94 | $17.015 | 7,806,206 | 10-13-2023 |
$18.95 | $18.82 | $18.95 | $18.98 | $18.78 | 3,515,578 | 10-12-2023 |
$18.73 | $18.66 | $18.73 | $18.735 | $18.66 | 718,305 | 10-11-2023 |
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Monday, Gilead Sciences Inc (NASDAQ:GILD) agreed to acquire CymaBay Therapeutics Inc (NASDAQ:CBAY) for $32.50 per share i...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...